4
Changes in Ownership
LENZ Therapeutics, Inc. Filed Acc 0002015796-25-000003
Chief Commercial Officer sold 10,000 shares at an average $26.10 ($261,022)
- Chief Commercial Officer acquired 10,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Olsson Shawn Chief Commercial Officer | 2025-11-17 | Option exercise 10b5-1 | +10,000 | $2.08 | $20,800 | 14,733 | D |
| Olsson Shawn Chief Commercial Officer | 2025-11-17 | Sale 10b5-1 | −4,212 | $25.74 | $108,411 | 10,521 | D |
| Olsson Shawn Chief Commercial Officer | 2025-11-17 | Sale 10b5-1 | −5,788 | $26.37 | $152,612 | 4,733 | D |
| Derivatives | |||||||
| Olsson Shawn Chief Commercial Officer | 2025-11-17 | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 53,241 | D | ||
| Open-market sales · 10,000 sh · avg $26.10 · $261,022 | |||||||
Loading xslF345X05/wk-form4_1763596932.xml…